Caribou Biosciences

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.12 per share a year ago.

Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Lags Revenue Estimates

Caribou Biosciences focuses on allogeneic CAR-T therapies for hematological cancers and autoimmune diseases, leveraging its unique chRDNA genome-editing technology. In my view, CRBU's chRDNA platform offers precise genome editing and could potentially outperform competitors like Allogene Therapeutics. CRBU's flagship candidate, CB-010, shows promising results in Phase 1 trials for large B cell lymphoma, with long-term complete response rates.

Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing

BERKELEY, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced company leadership will participate in the following event and investor conferences:

Caribou Biosciences to Participate in Upcoming Investor Conferences

NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ:CRBU). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBU

-- Highly-experienced hematologist and oncologist with proven track record successfully driving global clinical development of CAR-T cell therapies -- BERKELEY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Tina Albertson, MD, PhD, as chief medical officer. Dr. Albertson brings 15 years of experience leading clinical drug development of cellular therapies and biologics. She will be responsible for strategic leadership of the clinical, regulatory, and medical affairs functions, and provide medical and operational leadership of Caribou's four clinical programs for hematologic malignancies and autoimmune diseases. Dr. Albertson will report to Rachel Haurwitz, PhD, Caribou's president and chief executive officer.

Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer

Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.48 per share a year ago.

Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Tops Revenue Estimates

Caribou Biosciences (CRBU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Caribou Biosciences, Inc. (CRBU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

NEW YORK, Aug. 03, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Caribou Biosciences, Inc. (“Caribou” or the “Company”) (NASDAQ: CRBU).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBU

-- Dr. Laufer is an immunologist advancing the scientific understanding and treatment of autoimmune diseases -- BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Terri Laufer, MD, to its scientific advisory board. Dr. Laufer is a leading rheumatologist known for her extensive research into immune cell regulation and dysfunction that leads to autoimmune diseases. She is an emeritus associate professor of medicine at the Perelman School of Medicine at the University of Pennsylvania and an attending rheumatologist at the Penn Presbyterian Medical Center and Philadelphia VA Medical Center.

Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board

Caribou Biosciences develops allogeneic therapies using CRISPR technology, focusing on hematologic cancers and autoimmune diseases. CB-010, CB-011, and CB-012 are in Phase 1 clinical trials, with CB-010 showing promising results for B cell non-Hodgkin lymphoma. Evercore downgraded CRBU's stock due to high COGS concerns, but its superior efficacy and safety might justify higher prices.

Caribou Biosciences: Promising Gene Editing Therapies With Strong Buy Potential

-- CB-010 allogeneic CAR-T cell therapy w ith partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER patients with partial HLA matching (≥4 alleles) --

Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

BERKELEY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company's participation in the following event and investor conferences:

Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences

Revance Therapeutics

Verve Therapeutics

Like achieving a hole-in-one, holding a tenbagger is one of the best results any investor could wish for. A term popularized by legendary investor Peter Lynch, these stocks are innovators with the potential to grow exponentially.

3 Underappreciated Stocks That Could 10x in 10 Years

Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.46 per share a year ago.

Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates

BERKELEY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts have been accepted for poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31-June 4, 2024 in Chicago, Illinois.

Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Caribou Biosciences, Inc. is expected to produce results from phase 1 ANTLER study, using CB-010 for the treatment of 2nd-line large B-cell lymphoma patients, at medical meeting Q2 of 2024. Initial dose escalation data from the phase 1 ANTLER study indicated that CB-010 was able to generate a 90% objective response rate for patients with relapsed or refractory LBCL. Clearance was given by the FDA to initiate a phase 1 study using CB-010 for patients with lupus nephritis and extrarenal lupus; Trial initiation expected by the end of 2024.

Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value

BERKELEY, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract on the efficient use of Cas12a chRDNA genome-editing technology for in vivo hepatic gene disruption has been accepted for an oral presentation at the 27th annual meeting of the American Society of Gene and Cell Therapy (ASGCT), which is being held May 7-11, 2024, in Baltimore, Maryland.

Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

-- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Driven by encouraging initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical development has expanded to include autoimmune diseases --

Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus

HireRight GIS Group Holdings LLC

NEW YORK--(BUSINESS WIRE)---- $CRBU #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HireRight Holdings Corp. (“HireRight Holdings” or “the Company”) (NYSE: HRT). Investors who purchased HireRight Holdings securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRT. Investigation Details: The investigation into HireRight Holdings focuses on its proposed sale to.

HireRight Holdings Corp. (HRT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Caribou Biosciences, Inc. (CRBU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Caribou Biosciences, Inc. (CRBU) Rating Upgrade to Buy

Caribou Biosciences announced that it has paused the development of experimental cell therapy CB-020. The company still has three programs in clinical testing.

Why Caribou Biosciences Stock Is Crashing Today

-- 30 th patient dosed in CB-010 ANTLER Phase 1 trial dose expansion; initial dose expansion data and RP2D to be disclosed in Q2 2024 -- -- 1 st patient dosed in CB-012 AMpLify Phase 1 trial for patients with r/r AML --

Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

There's a new bull market, and it's lifting biotech stocks once again. Caribou Biosciences already has some good data and regulatory buy-in.

2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare

CRBU has provided regulatory and clinical updates in the past couple of months, but hasn't rallied quite like other biotech names. CRBU achieved alignment with the FDA on the comparator arm for its pivotal study of CB-010, and confirmed further data from the phase 1 ANTLER study in Q2'24. CRBU has progressed to the third dose level of CB-011 in the CaMMouflage study, and confirmed initial data are expected by year-end 2024.

Caribou Biosciences: Under The Radar With Catalysts Approaching

Catalyst Pharmaceuticals

Recursion Pharmaceuticals

Catalyst buys appealing medicines or pharmaceutical assets and gets them out the door. Recursion uses AI and vast biomedical data to discover and exploit leads for new drugs.

News for Caribou Biosciences Stock (CRBU)